Cathy Eng, MD (IMAGE) ECOG-ACRIN Cancer Research Group Caption Cathy Eng, MD (Vanderbilt-Ingram Cancer Center and ECOG-ACRIN Cancer Research Group), who is leading a new phase 3 trial for patients with metastatic anal cancer, says that the trial "is exploring whether the addition of immunotherapy to standard therapy will extend progression-free survival." Credit Vanderbilt-Ingram Cancer Center Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.